Skip to content

    Recently Viewed

      Listening...

      Home / Latest news /
      Johnson & Johnson signs a historic pledge to uphold the integrity of the scientific process in developing an investigational COVID-19 vaccine
      "Together, #WeStandWithScience" white text on red background

      Johnson & Johnson signs a historic pledge to uphold the integrity of the scientific process in developing an investigational COVID-19 vaccine

      In signing the pledge, we are joining eight other biopharmaceutical companies working on vaccine research and development in making the safety and well-being of vaccinated individuals our top priority.

      Share Article
      share to

      Today Johnson & Johnson is announcing that we, alongside eight other companies working on investigational COVID-19 vaccines, are signing a #WeStandWithScience pledge committed to upholding the integrity of the scientific process as we work towards potential global regulatory filings and approvals of the first vaccines for COVID-19.

      In signing the pledge, Johnson & Johnson, AstraZeneca, BioNTech, GlaxoSmithKline, Merck, Moderna, Inc., Novavax, Inc., Pfizer Inc. and Sanofi are underscoring a united commitment to develop and test potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles regarding the conduct of our clinical trials and the rigor of our manufacturing processes.

      As part of the pledge, the companies will continue to make the safety and well-being of vaccinated individuals their top priority, as well as work to ensure a sufficient supply and range of vaccine options, including those suitable for global access.

      The companies also pledge to only submit their vaccines for approval or emergency use authorization after demonstrating safety and efficacy through a Phase 3 clinical study that is designed and conducted to meet the requirements of expert regulatory authorities.

      To read more about the pledge, and why we believe rigorous science and safety must be the priority in vaccine development, go here.

      More from Johnson & Johnson

      Innovation
      Headshots of three Johnson and Johnson female scientists

      Meet 3 leaders who are breaking new ground for women in healthcare

      For International Women’s Day, celebrate the achievements of these amazing female scientists and researchers at Johnson & Johnson.
      Innovation
      Close-up of a woman with low vision receiving an eye exam exam with a doctor shining light into her left eye

      What is low vision?

      Low vision isn’t the same as blindness, but navigating daily life with it is still challenging. For Low Vision Awareness Month, learn the facts—plus, the promising treatment innovations that are in the works.
      Innovation
      A female scientist conducting research in a laboratory, focusing on orphan drugs for rare diseases

      What is an orphan drug?

      The need for these rare disease therapies is strong, and access to them can be lifesaving. Here’s how Johnson & Johnson is innovating to help give patients options.
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.